Want to see ACET full AI Analyst Report?
ACET Stock Chart & Stats
$7.79
-$0.63(-7.48%)
At close: 4:00 PM EDT
$7.79
-$0.63(-7.48%)
Day’s Range― - ―
52-Week Range$6.01 - $17.43
Previous Close$7.79
Volume71.21K
Average Volume (3M)90.40K
Market Cap
$88.84M
Enterprise Value-$12.49
Total Cash (Recent Filing)$118.19M
Total Debt (Recent Filing)$12.85M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Nov 11, 2026EPS Estimate
-1.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.45
Shares Outstanding9,361,490
10 Day Avg. Volume97,107
30 Day Avg. Volume90,404
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$22.50Price Target Upside188.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-7.55
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageLow leverage limits debt-related financial risk and preserves flexibility while Adicet funds clinical development. This provides a stronger balance-sheet base than highly indebted peers, although it does not offset the company’s substantial operating cash needs.
Narrowing Net LossesThe reduction in net losses indicates some improvement in cost or operating discipline over time. If sustained, this could extend the company’s funding runway and improve the economics of advancing its clinical pipeline, despite continued losses.
Governance ContinuityThe completed director elections and auditor ratification support continuity in oversight and strategic execution. Stable governance can help maintain focus on clinical development and financing priorities, though the event does not create a direct operating catalyst.
Bears Say
No Meaningful Commercial RevenueThe absence of meaningful revenue shows Adicet remains dependent on clinical progress and external funding rather than commercial sales. This limits operating leverage, makes profitability difficult to assess, and leaves future value tied primarily to pipeline execution.
High Ongoing Cash BurnPersistent annual cash outflows require continued access to external capital to fund research and clinical trials. This creates financing dependence and dilution risk, while limiting the company’s ability to absorb delays, unfavorable trial results, or higher development costs.
Shrinking Equity BaseThe substantial decline in equity reflects sustained losses and consumption of financial resources. A smaller capital base reduces resilience during prolonged development cycles and increases the likelihood that additional financing will be needed to support the pipeline.
Adicet Bio News
ACET FAQ
What was Adicet Bio Inc’s price range in the past 12 months?
Adicet Bio Inc lowest stock price was $6.01 and its highest was $17.43 in the past 12 months.
What is Adicet Bio Inc’s market cap?
Adicet Bio Inc’s market cap is $88.84M.
When is Adicet Bio Inc’s upcoming earnings report date?
Adicet Bio Inc’s upcoming earnings report date is Nov 11, 2026 which is in 82 days.
How were Adicet Bio Inc’s earnings last quarter?
Adicet Bio Inc released its earnings results on Aug 05, 2026. The company reported -$1.99 earnings per share for the quarter, missing the consensus estimate of -$1.692 by -$0.298.
Is Adicet Bio Inc overvalued?
According to Wall Street analysts Adicet Bio Inc’s price is currently Undervalued.
Does Adicet Bio Inc pay dividends?
Adicet Bio Inc pays a Quarterly dividend of $0.01 which represents an annual dividend yield of N/A. See more information on Adicet Bio Inc dividends here
What is Adicet Bio Inc’s EPS estimate?
Adicet Bio Inc’s EPS estimate is -1.39.
How many shares outstanding does Adicet Bio Inc have?
Adicet Bio Inc has 9,361,490 shares outstanding.
What happened to Adicet Bio Inc’s price movement after its last earnings report?
Adicet Bio Inc reported an EPS of -$1.99 in its last earnings report, missing expectations of -$1.692. Following the earnings report the stock price went down -13.428%.
Which hedge fund is a major shareholder of Adicet Bio Inc?
Currently, no hedge funds are holding shares in ACET
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (188.83% Upside)
$22.50 (188.83% Upside)
Blogger Sentiment
Bullish
ACET Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 77.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.08%
Trailing 12-Months
Company Description
Adicet Bio Inc
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
ACET Stock 12 Month Forecast
Average Price Target
$22.50
▲(188.83% Upside)
Technical Analysis
Sutro Biopharma
―
PMV Pharmaceuticals
―
Gain Therapeutics
―
Immix Biopharma
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
21.99% Insiders
9.73% Mutual Funds
35.57% Other Institutional Investors
28.46% Public Companies and
Individual Investors